PL2490709T3 - Peptydowi agoniści GLP-2 - Google Patents

Peptydowi agoniści GLP-2

Info

Publication number
PL2490709T3
PL2490709T3 PL10825678T PL10825678T PL2490709T3 PL 2490709 T3 PL2490709 T3 PL 2490709T3 PL 10825678 T PL10825678 T PL 10825678T PL 10825678 T PL10825678 T PL 10825678T PL 2490709 T3 PL2490709 T3 PL 2490709T3
Authority
PL
Poland
Prior art keywords
agonists
peptidic glp
peptidic
glp
Prior art date
Application number
PL10825678T
Other languages
English (en)
Inventor
Sudarkodi Alagarsamy
Guangcheng Jiang
Pierre Riviere
Claudio Daniel Schteingart
Javier Sueiras-Diaz
Kazimierz Wisniewski
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL2490709T3 publication Critical patent/PL2490709T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
PL10825678T 2009-10-23 2010-10-21 Peptydowi agoniści GLP-2 PL2490709T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25449009P 2009-10-23 2009-10-23
EP09173900A EP2314616A1 (en) 2009-10-23 2009-10-23 Peptidic GLP-2 agonists
EP10825678.5A EP2490709B1 (en) 2009-10-23 2010-10-21 Peptidic glp-2 agonists
PCT/US2010/053570 WO2011050174A1 (en) 2009-10-23 2010-10-21 Peptidic glp-2 agonists

Publications (1)

Publication Number Publication Date
PL2490709T3 true PL2490709T3 (pl) 2015-04-30

Family

ID=41572524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10825678T PL2490709T3 (pl) 2009-10-23 2010-10-21 Peptydowi agoniści GLP-2

Country Status (19)

Country Link
US (1) US8580918B2 (pl)
EP (2) EP2314616A1 (pl)
JP (1) JP5755653B2 (pl)
KR (1) KR101794781B1 (pl)
CN (1) CN102711802B (pl)
AR (1) AR079877A1 (pl)
AU (1) AU2010310665B2 (pl)
CA (1) CA2777758C (pl)
DK (1) DK2490709T3 (pl)
ES (1) ES2530615T3 (pl)
JO (1) JO3026B1 (pl)
NZ (1) NZ599137A (pl)
PL (1) PL2490709T3 (pl)
PT (1) PT2490709E (pl)
RS (1) RS53882B1 (pl)
RU (1) RU2551977C2 (pl)
SI (1) SI2490709T1 (pl)
TW (1) TWI482627B (pl)
WO (1) WO2011050174A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015160703A1 (en) * 2014-04-14 2015-10-22 Nps Pharmaceuticals, Inc. Treatment methods for gut-mediated hiv immune dysfunction
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US9783766B2 (en) 2015-04-03 2017-10-10 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
ES2963725T3 (es) 2016-07-11 2024-04-01 Opko Biologics Ltd Factor VII de coagulación de acción prolongada y métodos para producir el mismo
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN113710692A (zh) 2019-02-11 2021-11-26 Opko生物科学有限公司 长效glp-2类似物
CA3156985A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
GB202003762D0 (en) * 2020-03-16 2020-04-29 Heptares Therapeutics Ltd GLP receptor agonists
JP2023517766A (ja) * 2020-03-16 2023-04-26 ヘプタレス セラピューティクス リミテッド 経口glp受容体アゴニスト
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
CA3182260A1 (en) * 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
BR112023014978A2 (pt) 2021-01-28 2023-11-07 Vectivbio Ag Composições e métodos para o tratamento da doença do enxerto contra o hospedeiro

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
ES2188929T3 (es) * 1996-04-12 2003-07-01 Ontario Inc 1149336 Analogos 2-peptidicos de tipo glucagon.
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1980572A1 (en) * 2001-02-16 2008-10-15 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
RU2005114512A (ru) * 2002-10-14 2006-12-27 Ново Нордиск А/С (DK) Варианты глюкагон-подобного пептида-2
EP2295452A1 (en) * 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
KR101527233B1 (ko) * 2006-11-08 2015-06-08 질랜드 파마 에이/에스 선택적인 글루카곤 유사 펩티드-2(glp-2) 유사체

Also Published As

Publication number Publication date
AR079877A1 (es) 2012-02-29
AU2010310665B2 (en) 2014-10-23
EP2490709B1 (en) 2014-11-26
TWI482627B (zh) 2015-05-01
KR20120100942A (ko) 2012-09-12
ES2530615T3 (es) 2015-03-04
KR101794781B1 (ko) 2017-11-09
RU2012116046A (ru) 2013-11-27
PT2490709E (pt) 2015-03-04
JP5755653B2 (ja) 2015-07-29
WO2011050174A1 (en) 2011-04-28
TW201119668A (en) 2011-06-16
NZ599137A (en) 2013-04-26
SI2490709T1 (sl) 2015-04-30
RU2551977C2 (ru) 2015-06-10
DK2490709T3 (da) 2015-01-05
JP2013508398A (ja) 2013-03-07
EP2314616A1 (en) 2011-04-27
CN102711802A (zh) 2012-10-03
AU2010310665A1 (en) 2012-05-03
CN102711802B (zh) 2017-03-22
EP2490709A4 (en) 2013-05-15
EP2490709A1 (en) 2012-08-29
JO3026B1 (ar) 2016-09-05
US8580918B2 (en) 2013-11-12
CA2777758A1 (en) 2011-04-28
CA2777758C (en) 2018-06-05
US20120231999A1 (en) 2012-09-13
RS53882B1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
EP2490709A4 (en) GLP-2 RECEPTOR AGONISTS
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
EP2420634A4 (en) CONNECTOR
ZA201702958B (en) Novel npr-b agonists
EP2387850A4 (en) OBJECTS ASSOCIATED WITH A VIDEO
HK1171228A1 (en) Mglu2 agonists mglu2
GB0918585D0 (en) Plunger
DK2464943T3 (en) Systemintegration
GB0914038D0 (en) Connection
GB2471091B (en) Connection arrangement
GB0900924D0 (en) Instant kofta
HK1173659A1 (en) Peptidic glp-2 agonists glp-2
ZA201202724B (en) Peptidic glp-2 agonists
GB0903640D0 (en) Quick draw
AU4925P (en) Bonscawi Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
AU4926P (en) Bonscalib Scaevola aemula
HU0900116D0 (en) Spherical dimensions
GB0918357D0 (en) Bébé connection
GB0814690D0 (en) Quick draw
GB0803410D0 (en) Quick draw
GB0904054D0 (en) Compposting procedure
GB0916536D0 (en) Glycobiological surfaces